ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
The importance of partnering for bioanalytical studies
BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
Mitigating the impact of COVID-19 on CV trials and participants
A thought leadership article authored by Jack Martin, Mary Jane Geiger and Deirdre Albertson which focuses on navigating cardiovascular clinical trials during COVID-19.
Here’s what we have to do to show a coronavirus vaccine works
A article featuring expert commentary from ICON's Cynthia Dukes about the development of a vaccine for COVID-19.
Improving access and reimbursement for specialty therapies
ICON experts discuss how clinical development can better satisfy the evidence needs of HTA bodies and payers.
Women in healthcare: Dr. Nuala Murphy
PharmaTimes interviews Dr. Nuala Murphy, ICON's President of Clinical Research Services.
Ex-AstraZeneca exec Kristen Buck hops aboard ICON as CMO
Dr. Kristen Buck joins ICON as its new chief medical officer.
While the world waits
ICON's Cindy Dukes considers the best practices for developing a vaccine and treatments for COVID-19 in this thought leadership article.
ICON nabs former Optum, FDA and AstraZeneca exec as new chief medical officer
FierceBiotech reports on ICON's appointment of Dr. Kristen Buck as its new chief medical officer.
Company of the Month April 2020: ICON plc’s Q1 figures indicate strong growth
Business & Finance names ICON as 'Company of the Month' for April 2020
The U.S. biosimilars market: Shaking the “laggard” label
An article by Katya Svoboda and Bob Swann which explores the differences in the regulatory processes and the market dynamics of the US and the EU which account for much of the discrepancy in the uptake of biosimilars.